112 of 114 Studies: What the Epidemiological Evidence Actually Shows About Water-Damaged Buildings

Most people who encounter the claim that "there's no evidence mold causes serious illness" assume they're hearing the scientific consensus. They aren't. They're hearing a position that traces back to a single 2002 paper, authored by expert witnesses earning $500+/hour testifying against mold plaintiffs, whose conflicts of interest were documented in a peer-reviewed critique, and whose publisher removed it from their own website in 2014 without replacement.

Meanwhile, 112 of 114 epidemiological studies spanning 273,000+ subjects across 30+ countries support a link between water-damaged buildings and single- and multi-system illness. The question isn't whether evidence exists. The question is why one retracted paper still shapes the conversation.

Below, we walk through the findings of Dooley and McMahon's 2020 systematic review and the institutional history that produced the "no evidence" position it contradicts.

Disclosure: Dr. Scott McMahon, co-author of the Dooley-McMahon 2020 review, is MoldCo's Medical Director. We believe transparency about this relationship strengthens rather than undermines the discussion. The study was peer-reviewed and published in Internal Medicine Review, and its findings are consistent with reviews conducted by the Institute of Medicine (2004), the U.S. Government Accountability Office (2008), and the World Health Organization (2009).

Key findings

• 112 of 114 (98.2%) epidemiological studies published between 2011 and 2018 found associations between water-damaged buildings and adverse health effects (Dooley and McMahon, 2020)
• Effects spanned respiratory, neurological, cognitive, general, musculoskeletal, gastrointestinal, mental health, immune, ophthalmic, otolaryngology, neonatal/pregnancy, and dermatological systems
• The studies collectively covered 273,000+ subjects across 30+ countries on 5 continents
• 251 individual associations reported odds ratios or relative risks of 2.0 or higher across 79 articles
• The "no evidence" position originated from the ACOEM 2002 paper, which its own publisher removed in 2014 after conflict-of-interest documentation emerged
• A separate 2025 review covering 30 years of research (by Shoemaker, McMahon, and others, not Dooley) revisited this body of evidence and cited the Dooley-McMahon findings

If you suspect your environment may be contributing to your symptoms, you can take our free assessment to see if your experience is consistent with what these studies document.

Evidence

The claim you've probably heard

If you've looked into mold illness, you've likely encountered some version of this statement: "There's no credible evidence that indoor mold causes illness beyond allergies and asthma."

It shows up in insurance claim denials. It appears in occupational medicine guidelines. It gets repeated by physicians who learned it during training. And for a long time, it carried the weight of two professional organizations behind it: the American College of Occupational and Environmental Medicine (ACOEM) and the American Academy of Allergy, Asthma & Immunology (AAAAI).

The claim feels authoritative. But it rests on a surprisingly narrow foundation.

"My life would likely have been quite different the past 8 years had MoldCo been around when I found mold in my house in 2017. It's been a journey even talking publicly about mold illness since it sounds like quackery. Getting help has been even harder. Most doctors downplay the impact of mold."

MoldCo patient

That experience isn't a failure of individual doctors. It's the downstream effect of a specific paper that shaped two decades of institutional guidance, one that told clinicians mold couldn't be responsible for serious health problems.

Where the "no evidence" position came from

In 2002, ACOEM published a position statement titled "Adverse Human Health Effects Associated with Molds in the Indoor Environment." The paper argued that indoor mold was unlikely to cause illness beyond allergies and infection. It also included a mathematical argument that insufficient mycotoxin accumulates indoors to cause disease.

This paper became the backbone of mold litigation defense. Courtrooms cited it, insurance companies referenced it in denials, and the AAAAI echoed it in their own 2006 position statement.

In 2007, The Wall Street Journal reported on the financial connections between the paper's authors and the defense litigation industry. In 2008, a peer-reviewed critique by James Craner documented undisclosed conflicts of interest: the authors had been earning substantial fees as expert witnesses testifying against mold plaintiffs.

By 2014, ACOEM removed the paper from its own website without issuing a replacement. The position wasn't updated or revised. It was simply withdrawn.

But the ideas it introduced didn't disappear. They're still embedded in clinical training materials, insurance protocols, and the reflexive skepticism many physicians bring to mold-related complaints.

What 114 studies actually show

In 2020, Dooley and McMahon published a systematic review of mold research literature from 2011 to 2018 in Internal Medicine Review. The review examined 114 epidemiological studies covering 273,000+ subjects across more than 30 countries.

The result: 112 of 114 studies (98.2%) found associations between water-damaged buildings and adverse health effects.

This wasn't a narrow finding about sneezing and wheezing. The associations spanned multiple organ systems.

System-by-system concordance

The Dooley-McMahon 2020 review categorized studies by the body system affected. What it found challenges the idea that mold illness is limited to respiratory problems and infections.

Across the 114 studies, associations between water-damaged buildings and ill health turned up in one domain after another: cognitive (memory, concentration, executive function); general symptoms (the review's umbrella term, covering things like fatigue and headache in some studies); and neurological, musculoskeletal, gastrointestinal, mental-health, immune, ophthalmic, otolaryngology, neonatal/pregnancy, and dermatological effects. Respiratory effects, the one category ACOEM and AAAAI always acknowledged, were among the most consistently reported.

One caveat matters for honesty. Most of these studies reported associations; the share that reached conventional statistical significance was lower and varied by system. Among the cognitive studies, for instance, 7 of 16 (44%) reached significance, and 4 of 10 (40%) of the neurological studies did. So the point isn't that every study proved every symptom. It's that the direction of the evidence is consistent across many organ systems at once, which is the opposite of what you would expect if mold illness were confined to allergy and asthma.

A separate 2025 systematic review on fatigue specifically examined fatigue as a documented effect of mold and dampness exposure, and a 2024 state-of-the-science review by Gatto et al. documented mental-health associations across 19 studies.

One pattern stands out. The non-respiratory symptoms that patients are most often told "can't be mold" show up across this literature too, not just respiratory complaints. The evidence reaches well beyond allergy and asthma.

This is what the data looks like for patients whose symptoms were dismissed.

"Exposed to high levels of toxic mold for months in a rental home. Brain fog, fatigue, sick more often, working memory clobbered. Treatment with MoldCo has been a huge blessing, finally recovering. If not for them mold wouldn't even be on my radar as a potential cause. Most doctors aren't trained to diagnose it."

MoldCo patient

If you recognize these patterns in your own experience, a structured evaluation can help determine whether your environment may be a contributing factor. MoldCo's provider-supported assessments use the biomarkers documented in these studies to help you explore whether mold-related illness may be involved. You can also take our free assessment to see if your symptoms are consistent with mold-related illness.

The institutional evidence trail

The Dooley-McMahon 2020 review didn't emerge in isolation. It built on a progression of institutional findings that each pointed in the same direction.

IOM 2004: The Institute of Medicine published Damp Indoor Spaces and Health, finding sufficient evidence linking damp indoor environments to upper respiratory symptoms, coughing, wheezing, and asthma. The report stated more research was needed for other health effects. It was a conservative, carefully hedged conclusion. It was also correct as far as it went.

But something happened in translation. The IOM report's press release headlined "Evidence Does Not Support Links to Wider Array of Illnesses." For years, that headline was quoted as evidence of absence, when the report itself called for more research, not a closed question.

Dooley-McMahon 2020 is the answer to the question IOM 2004 asked.

GAO 2008: The U.S. Government Accountability Office examined federal mold efforts against a backdrop of scientific and medical research increasingly indicating that indoor mold can pose a "widespread and, for some people, serious health threat." The accompanying EPA-sponsored survey estimated 4.6 million of 21.8 million U.S. asthma cases were associated with dampness and mold, at a national annual cost of approximately $3.5 billion. The GAO criticized fragmented federal research efforts and inconsistent guidance across agencies.

The World Health Organization published guidelines in 2009 recognizing health effects of indoor dampness and mould that extend beyond allergic responses.

In 2011, Mendell et al. published a comprehensive review in Environmental Health Perspectives (an NIH journal) that independently confirmed associations between dampness, mold, and both allergic and non-allergic health effects.

Cox-Ganser 2015: A NIOSH researcher reviewed the state of evidence post-IOM 2004, a descriptive review reporting the need to investigate nonallergic mechanisms. This is a government occupational health researcher, not a CIRS advocate, noting that the evidence pointed beyond the allergic framework.

Hope (2013) published a mechanism review bridging epidemiology and biology, examining innate immune activation, neurological effects, and multi-system inflammatory responses from water-damaged building exposure.

The institutional evidence doesn't tell a story of doubt. It tells a story of accumulating certainty: from IOM 2004's cautious "more research needed" to Dooley-McMahon 2020's 98.2% concordance across 114 independent studies.

Methodology

The Dooley-McMahon 2020 review followed a systematic approach to identify, screen, and categorize epidemiological studies on health effects of water-damaged buildings.

Scope: Studies published from 2011 through 2018, examining health effects of indoor microbial growth or dampness in water-damaged buildings.

Study selection: 114 epidemiological studies met inclusion criteria, covering populations in 30+ countries across 5 continents.

Analysis: Each study was classified by whether it found or didn't find associations between water-damaged buildings and health effects. Studies were further categorized by organ system affected. The 251 associations with odds ratios or relative risks of 2.0 or higher across 79 articles indicate effect sizes substantially above chance.

Follow-up work: In 2025, Shoemaker, McMahon, and colleagues published a perspectives review covering 30 years of research in Medical Research Archives that revisits this body of evidence and references the Dooley-McMahon findings (it is not a Dooley-McMahon follow-up and does not independently re-derive the 98.2% figure). A separate 2025 review on fatigue specifically examined that symptom's association with mold and dampness exposure. Additionally, Schrantz et al. (2025) published a review connecting indoor environmental assessment and remediation to clinical outcomes, further bridging building science and medical evidence.

Limitations

We want to be direct about what this evidence does and doesn't show.

This is epidemiological evidence, not proof of causation. Epidemiological studies establish associations between exposures and outcomes. They don't prove that water-damaged buildings directly cause multi-system illness in any individual case. We're stating this clearly because intellectual honesty matters more to us than rhetorical advantage.

That said, 98.2% concordance across 114 independent studies, with 273,000+ subjects in 30+ countries, is exactly what epidemiological evidence looks like when an association is real. The smoking-lung cancer link was established through the same kind of evidence: consistent, strong associations replicated across independent populations.

Two studies found no association. Out of 114, two didn't find a link between water-damaged buildings and health effects. We won't pretend they don't exist. A 1.8% non-concordance rate falls within the standard alpha-error rate (<5%) expected in any body of epidemiological research. These two studies don't invalidate the other 112. They're what statistical noise looks like in a large evidence base.

Publication journal. The Dooley-McMahon 2020 review was published in Internal Medicine Review, which isn't among the highest-impact-factor medical journals. The study's value lies in its systematic scope (114 studies, 273,000+ subjects) and its concordance with findings from the IOM, WHO, GAO, NIH-published reviews, and NIOSH researchers.

Conflict-of-interest transparency. Dr. McMahon is a co-author of the reviewed study and serves as MoldCo's Medical Director. Readers should weigh this relationship when evaluating our presentation of the data. The underlying studies cited in the Dooley-McMahon review were conducted by independent researchers worldwide and are individually accessible through the citations provided.

What this means

The "no evidence" claim about mold illness wasn't overturned by new research appearing out of nowhere. ACOEM's own publisher removed the 2002 paper. The AAAAI 2006 statement was criticized in the Wall Street Journal and is now archived, not current. And 112 of 114 independent epidemiological studies, spanning dozens of countries and hundreds of thousands of subjects, converge on the same finding: water-damaged buildings are associated with health effects that go well beyond allergies and asthma.

If you've been told your symptoms can't be related to mold, or that the science doesn't support it, you now have the citation to check for yourself.

The evidence base is there. It's been there. The question for anyone experiencing unexplained multi-system symptoms in the context of a water-damaged environment isn't whether evidence exists. It's what to do with it.

"I've had multiple mold exposures over the years, in my own home, in hotels, and in short-term rentals, and MoldCo has been the only team able to give me clear answers, real science, and compassionate support. Their testing process is straightforward, their reports are actionable, and their guidance has genuinely changed the way I understand and manage my health."

MoldCo patient

If you're experiencing symptoms consistent with what these studies document, and you suspect your environment may be a factor, a provider-supported evaluation can give you clarity. MoldCo's approach is guided by the same research base described in this article. You don't need to commit to a diagnosis or a protocol. You can start by getting the information you need to explore whether mold could be contributing.

FAQ

Does the Dooley-McMahon review prove that mold causes illness?

No. Epidemiological evidence establishes associations, not causation. What the review shows is that 98.2% of 114 independent studies found associations between water-damaged buildings and health effects in one or more body systems. This level of concordance across 273,000+ subjects in 30+ countries is consistent with a real association, but it doesn't prove a causal mechanism in any individual case.

Who are Dooley and McMahon?

Ming Dooley and Dr. Scott McMahon are researchers who have co-authored multiple peer-reviewed publications on health effects of water-damaged buildings. Dr. McMahon is also MoldCo's Medical Director, a fact we've disclosed in this article. Their 2020 review was published in Internal Medicine Review and has been followed by a 2025 systematic review on fatigue. (A separate 2025 perspectives review covering 30 years of research by Shoemaker, McMahon, and colleagues, not Dooley, revisits this evidence base; it is not a follow-up to the Dooley-McMahon review.)

What happened to the ACOEM 2002 position paper?

ACOEM published a position statement in 2002 arguing indoor mold was unlikely to cause illness beyond allergies and infection. The paper's authors' conflicts of interest were documented in a 2008 peer-reviewed critique. By 2014, ACOEM removed the paper from its own website. For more on how professional society positions on mold have evolved, see our article on the ACMT 2025 position statement.

What about the IOM 2004 report?

The Institute of Medicine's Damp Indoor Spaces and Health found sufficient evidence for respiratory effects and called for more research on other systems. That report is over 20 years old. The Dooley-McMahon 2020 review, covering 114 studies published through 2018, is a direct answer to IOM's call for further research.

Are there symptoms beyond respiratory that the evidence supports?

Yes. The review reported associations across many body systems, including cognitive, general, neurological, musculoskeletal, gastrointestinal, mental-health, and respiratory effects. One caveat: most were reported as associations, and the share reaching conventional statistical significance was lower and varied by system (for example, 7 of 16 cognitive studies and 4 of 10 neurological studies reached significance). The breadth across domains is the real point: the evidence isn't confined to allergy and asthma. For a full overview of mold-related symptoms, see our mold exposure symptoms guide.

How can I find out if mold is contributing to my symptoms?

A structured evaluation that looks at your symptoms, exposure history, and relevant biomarkers can help determine whether your environment may be a factor. MoldCo's provider-supported evaluations are available in a growing number of states and are designed to help you get clarity without committing to a specific protocol upfront. The goal is to find out whether mold could be contributing.

Any health-related claims made on this site have not been evaluated by the Food and Drug Administration (FDA). The information provided on this site is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. MoldCo assumes no responsibility or liability for any errors or omissions in the content of the references, nor for any actions taken in reliance thereon.